Zusammenfassung
Klinische Studien sind strukturierte Erfahrung. In ihnen geht es darum, unter transparenten, vorher festgelegten, überprüfbaren Bedingungen Informationen über die Wirksamkeit und Verträglichkeit von Therapien zu gewinnen (DeMets 2012).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsLiteratur
Abel U (1995) Die zytostatische Chemotherapie fortgeschrittener Karzinome, 2. vollst. überarbeitete Aufl. Hippokrates, Stuttgart, S 56ff
Abel U, Windeler J (1995) Erkenntnistheoretische Aspekte klinischer Studien. 1. Irrtümer in der Bewertung medizinischer Therapien – Ursachen und Konsequenzen. Internist Prax 35:613–629
Abel U, Koch A (1999) The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol 52:487–497
Adam J, Förster W (1996) Meta-Analysen – wirklich der Weisheit letzter Schluß? Münch Med Wschr 138:37–39
Bischoff W, Miller F (2009) A seamless Phase II/III design with sample-size re-estimation. J Biopharm Stat 19:595–609
Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312:1215–1218
Borzak S, Ridker PM (1995) Discordance between metaanalyses and large-scale randomized, controlled trials. Ann Intern Med 123:873–877
Bretz F, Schmidli H, Koenig F, Racine A, Maurer W (2006) Confirmatory seamless Phase II/III clinical trials with hypotheses selection at interim: general concepts (with Discussion). Biometrical Journal 48: 623–634
Bretz F, Koenig F, Brannath W, Glimm E, Posch M (2009) Adapative designs for confirmatory clinical trials. Stat Med 28:1181–1217
Brufman G, Colajori E, Ghilezan N, Lassus M, Martoni A, Perevodchikova N, Tosello C, Viaro D, Zielinski C, and the Epirubicin High-Dose (HEPI010) Study Group (1997) Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Annals of Oncology 8: 155–62
Buyse M, Pedbois P (1996) On the relationship between response to treatment and survival time. Stat Med 15:2797–2812
Chan A-W, Hrosbjartsson A, Haahr MT, Gotsche PC, Altman DC (2004) Empirical evidence for selective reporting of outcomes in Randomized Trials. Comparison of protocols to published articles. JAMA 291:2457–2465
Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D (2013) SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med 158:200–207
Chan A-W, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schluz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D (2013) SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 346:e7586
Chevret S (2012) Bayesian adaptive clinical trials: a dream for statisticians only? Statist Med 31:1002–1013
CHMP (Committee for Medicinal Products for Human Use) (2002) Points to consider on multiplicity issues in clinical trials. EMA, London. http://www.ema.europa.eu/pdfs/human/ewp/090899en.pdf. Zugegriffen: 9. Mai 2013
CHMP (Committee for Medicinal Products for Human Use) (2005) Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMA, London. http://www.ema.europa.eu/pdfs/human/ewp/13939104en.pdf.: Zugegriffen: 9. Mai 2013
CHMP (Committee for Medicinal Products for Human Use) (2006) Guideline on the evaluation of anticancer medicinal products in man. EMA, London. http://www.ema.europa.eu/pdfs/human/ewp/020595en.pdf. Zugegriffen:).9. Mai 2013
CHMP (Committee for Medicinal Products for Human Use (2007a) Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. London. http://www.ema.europa.eu/pdfs/human/swp/2836707enfin.pdf. Zugegriffen: 9.Mai 2013
CHMP (Committee for Medicinal Products for Human Use (2007b) Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. EMA, London. http://www.ema.europa.eu/pdfs/human/ewp/245902enadopted.pdf. Zugegriffen: 9. Mai 2013
CHMP (Committee for Medicinal Products for Human Use) (2008) Appendix 1 to the Guideline on the evaluation of anticancer medicinal products in man. EMA, London. http://www.ema.europa.eu/pdfs/human/ewp/2799408en.pdf. Zugegriffen: 9. Mai 2013
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. J Clin Oncol 25:1753–1759
Chow SC, Liu J-P. (2004) Design and analysis of clinical trials. 2nd ed. Wiley, New York, S 44ff
Chow SC, Chang M (2007) Adaptive design methods in clinical trials. Chapman & Hall/CRC, Boca Raton
Concato J (2004) Observational versus experimental studies. What’s the evidence for a hierarchy? NeuroRx 1:341–437
CONSORT Statement (CONsolidated Standards of Reporting Trials), Consort Group, http://www.consort-statement.org/consort-statement.Zugegriffen: 9. Mai 2013
Cook DI, Gebski VJ, Keech AC (2004) Subgroup analysis in clinical trials. MJA 180:289–291
Cook TD, De Mets DL (2008) Introduction to statistical methods for clinical trials. Chapman & Hall/CRC, Boca Raton
Crowley J, Ankerst DP. (Hrsg) (2006) Handbook of statistics in oncology. 2nd edition. Chapman & Hall/CRC Press, Boca Raton, S 119ff
CTEP: Cancer Therapy Evaluation Program (NCI); NIH, Bethesda, MD http://ctep.cancer.gov/protocolDevelopment/templates_applications.htm. Zugegriffen: 9. Mai 2013
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB; International Committee of Medical Journal Editors (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet 364:911–912
DeMets DL (2012) Current development in clinical trials: issues old and new. Statist Med 31:2944–2954
DeMets DL, Pocock SJ, Julian DG (1999) The agonizing negative trend in monitoring of clinical trials. Lancet 354:1983–88
Dwan K, Altman DG, Arnaiz J, Bloom J, Chan A-W, Cronin E, Decullier E, Easterborrk PJ, von Elm E, Gamble C, Ghersi D, Ionnidis JPA, Simes J, Williamson PR (2008) Systematic review of the empirical evidence of study publication and outcome reporting bias. PLoSONE 3(8):e3081.doi:10.1371/journal.pone.0003081
Easterbrook PhJ, Berlin JA, Gopalan R, Matthews DR (1991) Publication bias in clinical research. Lancet 337:867–872
ECOG (Eastern Cooperative Oncology Group) Coordinating Center, Boston MA, http://www.ecog.org. Zugegriffen: 9. Mai 2013
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Europ J Cancer 45:228–247
Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL (2012) Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 118:147–156
Edler L (1993) Phase-II-Studien in der Onkologie: Wie viele Patienten sind erforderlich? Tumordiagn Ther 14:1–9
European Medicines Agency (1998) ICH Topic E8: Note for Guidance on general considerations for clinical trials. CPMP/ICH/291/95. London. http://www.ema.europa.eu/pdfs/human/ich/029195en.pdf. Zugegriffen: 9. Mai 2013
European Medicines Agency (2013) Clinical efficacy and safety guidelines. http://www.ema.europa.eu/htms/human/humanguidelines/efficacy.htm. Zugegriffen: 9. Juni 2013
Eyawo O, Lee C-W, Rachlis B, Mills EJ (2008) Reporting of non-inferiority and equivalence randomized trials for major prostaglandins: A systematic survey of the ophthalmology literature. Trials 9:69
Fairclough DL (2010) Design and analysis of quality of life studies in clinical trials. Second ed. CRC Press, Boca Raton
Fayers PM, Machin D (2007) Quality of life: the assessment, analysis and interpretation of patient-reported outcomes. 2nd ed. Wiley, Chichester
Fanelli D (2009) How many scientist fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoSONE 4(5):e5738.doi:10.1371/journal.pone.0005738
Fang YJ, Su Z (2012) Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: a resampling approach. Contemp Clin Trials 33:138–142
FDA (2007) Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. US. Dept Health and Human Services, Rockville, MD. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf. Zugegriffen: 9. Mai 2013
FDA (2009) Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. Draft Guidance.US. Dept Health and Human Services, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Zugegriffen: 9. Mai 2013
Fleming TR (2005) Surrogate Endpoints and FDA’s accelerated approval process. Health Affairs 24:67–78
Fossâ SD, Skovlund E (2000) Interim analyses in clinical trials: why do we plan them? J Clin Oncol 18:4007–4008
Friede T, Kieser M (2001) A comparison of methods for adaptive sample size adjustment. Stat Med 20:3861–3873
Friede T, Kieser M (2006) Sample size recalculation in internal pilot study designs: a review. Biom J. 48:537–555
Friedman LM, Furberg CD, DeMets DL (2010) Fundamentals of Clinical Trials. 4th ed. Springer New York
Gan HK, You B, Pond GR, Chen EX (2012) Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer. J Natl Cancer Inst 104:590–598
Glasziou P, Chalmers I, Rawlins M, McCulloch P (2007) When are randomised trials unnecessary? Picking signal from noise. BMJ 334:349–351
Granone P, Trodella L, Margaritora S et al. (2000) Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study. Eur J Cardiothorac Surg 18:418–424
Green S, Benedetti J, Crowley J (1997) Clinical trials in oncology. Chapman & Hall, London
Guidance for Industry Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics. Draft Guidance 2011. Available online: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryIn formation/Guidances/UCM259421.pdf. Zugegriffen: 9. Mai 2013
Gupta SK (2011) Intention-to-treat concept: A review. Perspect Clin Res 2:109–112
Gupta SK (2011) Non-inferiority clinical trials: Practical issues and current regulatory perspective. Indian J Pharmacol 43:371–374
Hartz A, Bentler S, Charlton M, Lanska D, Butani, Y, Soomro GM, Benson K (2005): Assessing observational studies of medical treatments. Emerging Themes in Epidemiology 2:8. Available from: http://www.ete-online.com/content/2/1/8
Hollen PJ, Gralla RJ, Cox C, Eberly SW, Kris MG (1997) A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer 18:119–136
Hollinshead A (1991) Active specific immunotherapy and immunechemotherapy in the treatment of lung and colon cancer. Semin Oncol 7:199–210
Hollinshead AC, Stewart THM, Takita H, Dalbow M, Concannon J (1987) Adjuvant specific active lung cancer immunotherapy trials. Cancer 60:1249–1262
Iasonos A, Wilton AS, Riedel ER, Seshan VE, Spriggs DR (2008) A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials 5:465–477
Jennison C, Turnbull BW (2000) Group sequential methods with applications to clinical trials. Chapman & Hall, Boca Raton
Jennison C, Turnbull BW (2006) Confirmatory seamless phase II/III clinical trials with hypothesis selection at interim: opportunities and limitations. Biom J 48: 650–655
Julious SA (2010) Sample sizes for clinical trials. Chapman & Hall/CRC Press, Boca Raton
Kairalla JA, Coffey CS, Thomann MA, Muller KE (2012) Adaptive trial designs: a review of barriers and opportunities. Trials 13:145
Kreuser E-D, Fiebig HH, Scheulen ME et al. (1998) Standard operating procedures and organization. Onkologie 21 (Suppl 3):1–70
Kunz R, Khan KS, Kleinjen J, Antes G (2009) Systematische Übersichtsarbeiten und Meta-Analysen. Huber, Bern
Lai TL, Lavori PW, Shih M-L (2012) Adaptive Trial Designs. Annu Rev Pharmacol Toxicol 52:101–110
Lai TL, Lavori PW, Shih M-C (2012) Sequential design of Phase II–III cancer trials. Statist Med 31:1944–1960
Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I (2006) The case of the misleading funnel plot. BMJ 333:597–600
Lewis JA, Facey KM (1998) Statistical shortcomings in licensing applications. Stat Med 17:1663–1673
Little RJ, D’Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Neaton JD, Rotnitzky A, Scharfstein D, Shih WJ, Siegel JP, Stern H (2012) The prevention and treatment of missing data in clinical trials. New Engl J Med 367:1355–1360
Machin D, Campbell MJ, Tan SB, Tan SH (2009) Sample size tables for clinical studies. 3rd ed. Wiley, Chichester
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analysis of randomized controlled trials: the QUOROM statement. Lancet 354:1896–1900
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. JClin Epidemiol 62: 1006–1012
Moyé LA (2003) Multiple analyses in clinical trials: fundamentals for investigators. Springer, New York
Munro AJ (1998) What now for postoperative radiotherapy for lung cancer? Commentary. Lancet 352:250–251
Naylor CD (1997) Meta-analysis and the meta-analysis of clinical research. BMJ 315:617–619
Osoba D (2011) Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol 3:57–71
Piantadosi S (2005) Clinical trials: a methodological perspective. 2nd edition. Wiley, New York
Pilz LR, Manegold C, Schmid-Bindert G (2012) Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res 1:26–35
Pocock SJ (1983) Clinical trials – a practical approach. Wiley, Chichester
PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352:257–263
PORT Meta-analysis Trialists Group (2010) Postoperative radiotherapy in non-small-cell lung cancer (review) (2010) Cochrane Database Syst Rev; (2): CD002142. DOI: 10.1002/1465–1858.CD002142.pub2.
RANDI2 Randomization system, DKFZ Heidelberg, http://www.randi2.org. Zugegriffen: 9. Mai 2013
Randomizer (2013) Randomizer for clinical trials 1.8.3, Medizinische Universität Graz, Österreich, http://www.randi2.org/ https://www.randomizer.at/demo/web/about.php. Zugegriffen: 21. Juni 2013
Ranstam J, Buyse M, George SL et al. (2000) Fraud in medical research: an international survey of biostatisticians. Control Clin Trials 21:415–427
RECIST (Response Evaluation Criteria In Solid Tumors) Berlin, Germany. http://www.recist.com/
Rosenberger WF, Lachin JM (2002) Randomization in clinical trials: theory and practice. Wiley, New York
Royal Statistical Society (2007) Report of the Working Party on Statistical Issues in First-in-Man studies. www.rss.org.uk/main.asp?page=1713σ
Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D (2009) Randomized Phase II Designs. Clin Cancer Res 15:1883–1890
Sackett DL (1979) Bias in analytical research. J Chronic Disease 32:51–63
Sackett DL (1998) Was ist Evidenz-basierte Medizin? Editorial. In: Perleth M, Antes G (Hrsg) Evidenzbasierte Medizin. Wissenschaft im Praxisalltag. MMV Medizin Verlag, München, S 9–12
Salek S (1998) Compendium of quality of life instruments. Wiley, Chichester New York
Schrimpf D, Manegold C, Pilz LR (2013) Design of clinical studies: Adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC). Int J Clin Pharmaceutical Therapeutics 52:84–86
Schrimpf D, Pilz LR (2012) Adaptive randomization procedures for the web-based randomization system RANDI2. Int J Clin Pharmaceutical Therapeutics 52:85–86
Schrimpf D, Plotnicki L, Pilz LR (2011) Choice and simulation of the randomization procedure for clinical trials. Int J Clin Pharmaceutical Therapeutics 49:91–92
Schulz K, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. JAMA 273:408–412
Schulz KF, Altman DG, Moher D; CONSORT Group (2010) Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152:726–732
Schumacher M, Schulgen G (2008) Methodik klinischer Studien. 3. Aufl. Springer - New York - Heidelberg
Schwarzer G, Galandi D, Antes G, Schumacher M (2000) Meta-Analyse randomisierter klinischer Studien, Publikations-Bias und Evidence-based Medicine. Informatik, Biometrie und Epidemiologie in Medizin und Biologie 31:1–21
Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubenstein L, Ratein MJ, LeBlanc M, Stewart D, Crowley J, Groshan S, Humphrey JS, West P, Berry D (2010) The design of Phase II clinical trials testing cancer therapeutics: Consensus recommendations from the clinical trial design task force of the national Cancer Institute Investigational Drug Steering Committee. Clin Cancer Res 16:1764–1769
Soares HP, Kumar A, Daniels S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B (2005) Evaluation of new treatment sin radiation oncology. JAMA 293:970–978
Stallard N (2012) Optimal sample sizes for phase II clinical trials and pilot studies. Stat Med 31:1031–1042
Sylvester R, Bartelink H, Rubens R (1994) A reversal of fortune: practical problems in the monitoring and interpretation of an EORTC breast cancer trial. Stat Med 13:1329–1335
Tang J-L, Liu JLY (2000) Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiology 53:477–484
Tang PA, Bentzen, SM, Chen EX, Siu LL (2007) Surrogate endpoints for overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 29: 4562–4568
Trotta F, Apolone G, Garattini S, Tafuri G (2008) Stopping a trial early in oncology for patients or for industry? Ann Oncol 19:1347–1353
Unnebrink K, Windeler J (1999) Sensitivity analysis by worst and best case assessment: is it really sensitive? Drug Inf J 33:835–839
Vastag B (2006) Cancer fraud case stuns research community, prompts reflection on peer review process. JNCI 98:374–376
Vera-Badillo FE, Shapiro R, Ocana A, Amir E, Tannock IF (2013) Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (published in advance access) doi:10.1093/annonc/mds636
Vickers A, Goyal N, Harland R, Rees R (1998) Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin Trials 19:159–166
Wallack MK, Sivanandham M, Balch CM et al. (1995) A phase III randomized, double-blind, multi-institutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75:34–42
Wallack MK, Sivanandham M, Whooley B, Ditaranto K, Bartolucci AA (1996) Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial. Ann Surg Oncol 3:110–117
Wang M, Dignam JJ, Zhang QE, DeGroot JF, Mehta MP, Hunsberger S (2012) Integrated phase II/III clinical trials in oncology: A case study. Clin Trials 9:741–747
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine - reporting of subgroup analyses in clinical trials. New Engl J Med 357:2189–2194
Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Herman AA, Beveridge RA (2000) High-dose chemotherapy for high-risk primary breast cancer: an onsite review of the Bezwoda study. Lancet 355:999–1003
Weiss RB, Gill GG, Hudis CA (2001) An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol 19:2771–2777
Whitehead A (2002) Meta-analysis of controlled clinical trials. Wiley, Chichester
Windeler J (1993) Das Intention-to-treat-Prinzip in klinischen Arzneimittelprüfungen. Arzneimitteltherapie 11:103–111
Wittes J, Brittain E (1990) The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 9:65–72
Zohar S, Lian Q, Levy V, Cheung K, Ivanova A, Chevret S (2008) Quality assessment of Phase I dose-finding cancer trials: proposal of a checklist. Clin Trials 5:478–485
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pilz, L., Abel, U., Pritsch, M. (2013). Biometrie. In: Wannenmacher, M., Wenz, F., Debus, J. (eds) Strahlentherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-88305-0_15
Download citation
DOI: https://doi.org/10.1007/978-3-540-88305-0_15
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-88304-3
Online ISBN: 978-3-540-88305-0
eBook Packages: Medicine (German Language)